$CELU News

Celularity Receives Nasdaq Noncompliance Notice

Celularity Enters Settlement With Helena Global To Restructure Convertible Note Obligations, Including $500K Upfront And $100K Monthly Payments Plus Note Assignment

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

NEXGEL Appoints Ian Blackman as Chief Financial Officer

NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

NEXGEL, Inc. Q4 2025 Earnings Call Summary

Celularity Announces Closing of Transaction with NexGel

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Receives Nasdaq Notice Regarding Late Form 10-K Filing

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction

NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Celularity Signs $35M Agreements For Its Placental-Derived Biomaterials Portfolio

Joseph Dossantos, Acting CFO, Left Celularity On Feb 27, 2026; John Sprague Appointed As Acting CFO Of Co.

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses